Jpmorgan Chase & Co »

Intensity Therapeutics shares owned by Jpmorgan Chase & Co

Quarter-by-quarter ownership of Intensity Therapeutics (INTS) shares owned by Jpmorgan Chase & Co from 13F filings

Historical chart of Jpmorgan Chase & Co investment in Intensity Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Intensity Therapeutics held by Jpmorgan Chase & Co consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Intensity Therapeutics by Jpmorgan Chase & Co

Quarter filed Position value Share count Share price at filing
2024-03-31 $46k 8.9k 5.20
2023-12-31 $343 40 8.58
2023-09-30 $4 1 4.00

More positions owned by Jpmorgan Chase & Co

Microsoft Corp Common (MSFT)
Nvidia Corporation Common (NVDA)
SPDR S&P 500 ETF Ser 1 S&P Common (SPY)
Amazon Common (AMZN)
Apple Common (AAPL)
Meta Platforms Common (META)
Eli Lilly & Co Common (LLY)
Alphabet Common (GOOG)
Mastercard Incorporated Common (MA)
Unitedhealth Group Common (UNH)
Ishares Core S&p 500 Etf Fund (IVV)
Vanguard index Fds S&P 500 ETF Common (VOO)
Abbvie Common (ABBV)
Exxon Mobil Corp Common (XOM)
Alphabet Common (GOOGL)

View all positions for Jpmorgan Chase & Co

Top funds holding Intensity Therapeutics

Sapient Capital
Vanguard Group
Brown Advisory Holdings Incorporated
Sigma Planning
Geode Capital Management
Mesirow Financial Investment Management International Equity
One Charles Private Wealth Services
Sentinus
Lakeview Capital Partners
Qube Research & Technologies
BlackRock
Commonwealth Equity Services
Jpmorgan Chase & Co
Tower Research Capital
UBS Group

View all funds holding Intensity Therapeutics